EBR SYSTEMS INC (EBR)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EBR - EBR SYSTEMS INC

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -1.2
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.00

23 Dec
2024

0.000

OPEN

$1.00

0.000

HIGH

$1.05

771,164

LOW

$0.99

TARGET
$1.885 88.5% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
EBR: 1
Title FY24
Forecast		 FY25
Forecast
EPS (cps) - 18.4 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 2020202120222023
EPS Basic xxxxxxxxx-18.1
DPS All xxxxxxxxx0.0
Sales/Revenue xxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxx14.7
Net Operating Cash Flow xxxxxxxxx-49.3 M
Net Profit Margin xxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 2020202120222023
Return on Capital Employed xxxxxxxxx-95.69 %
Return on Invested Capital xxxxxxxxx-52.18 %
Return on Assets xxxxxxxxx-47.70 %
Return on Equity xxxxxxxxx-95.69 %
Return on Total Capital xxxxxxxxx-51.26 %
Free Cash Flow ex dividends xxxxxxxxx-49.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 2020202120222023
Short-Term Debt xxxxxxxxx0 M
Long Term Debt xxxxxxxxx61 M
Total Debt xxxxxxxxx61 M
Goodwill - Gross xxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxx106 M
Price To Book Value xxxxxxxxx4.11

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 2020202120222023
Capex xxxxxxxxx0.5 M
Capex % of Sales xxxxxxxxx-
Cost of Goods Sold xxxxxxxxx1 M
Selling, General & Admin. Exp & Other xxxxxxxxx51 M
Research & Development xxxxxxxxx32 M
Investments - Total xxxxxxxxx2 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

01/10/2024

1

Speculative Buy

$2.01

101.00%

Bell Potter notes EBR Systems has raised $50m for initial commercialisation for its WiSE-CRT cardiac pacing system with FDA approval expected in 1Q2025.

The funding is highlighted as pre-emptive the broker believes, providing sufficient cash for the next 18-months to cover a sales and marketing team, building up the manufacturing system, with more R&D into rechargeable battery capabilties.

Bell Potter still views a second funding raising as necessary to reach cashflow positive with the next raising possibly post the 2Q2026 results. The estimated amount is circa $66m at $1 per share.

Speculative Buy rating unchanged. Target rises to $2.01 from $1.96.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -17.10 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -18.16 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

22/10/2024

1

Overweight

$1.62

62.00%

Wilsons notes EBR Systems raised $50m to help fund activities for the FDA approval which is expected in March 2025.

The analyst maintains an Overweight rating and stresses the current target price of $1.62 can increase to $3 on the back of immediate "PMA-enabled indications" developing over the next 12-18 months.

Wilsons states WiSE tecnhology has the scope to move into the growing population of pacemaker patients who required left ventricular pacing.

FORECAST
Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -23.60 cents.
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -14.83 cents.
Access Extra Coverage Research History >

EBR STOCK CHART

FNArena News on EBR

1
Rudi’s View: Final Best Buys & Conviction Ideas

Dec 23 2024 - Rudi's View
2
Rudi’s View: Banks, WiseTech, Redox & Integral Diagnostics

Dec 19 2024 - Rudi's View
3
Rudi’s View: Best Buys & Smaller Cap Favourites

Dec 12 2024 - Rudi's View
4
Australian Broker Call *Extra* Edition – Oct 22, 2024

Oct 22 2024 - Daily Market Reports
5
FNArena Corporate Results Monitor – 28-08-2024

Aug 28 2024 - Australia

Latest Medical Equipment & Devices News

1
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps
2
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
3
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
4
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
5
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps
6
ResMed Silences The Doubters

Apr 29 2024 - Australia
7
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
8
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
9
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia
10
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024 - Rudi's View